All In MedTech

Device Trial Radar · NCT02145351

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)

Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Apr 7, 2014

Primary completion

May 9, 2022

Study completion May 9, 2022

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
May 22, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Determine the impact of restoring normal heart rate response during exercise and daily activity in patients with heart failure and a preserved ejection fraction (HFpEF) and chronotropic incompetence (CI).

Conditions

  • Heart Failure With a Preserved Ejection Fraction
  • Heart Failure, Diastolic
  • Chronotropic Incompetence

Interventions

  • Rate adaptive atrial pacing using a dual-chamber pacemakerDevice

    The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.

  • Pacemaker system will be implanted but set to Pacing Off.Device

    The identical pacing system will be implanted, but will be set to Pacing Off.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Oxygen Consumption (VO2) at Ventilatory Anaerobic Threshold (VAT)Time frame: baseline, after 4 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.